What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial
{{output}}
Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. Objective: We sought to determine the surv... ...
